Associated Genetic Biomarkers
IDH2 R140G is present in 0.02% of AACR GENIE cases, with non-small cell lung carcinoma having the greatest prevalence .
IDH2 R140G is a predictive biomarker for use of enasidenib in patients.
Of the therapies with IDH2 R140G as a predictive biomarker, 1 is FDA-approved and 1 has NCCN guidelines in at least one clinical setting.
Acute myeloid leukemia has the most therapies targeted against IDH2 R140G or its related pathways .
Acute Myeloid Leukemia -
|Biomarker Criteria:||Predicted Response: Primary Sensitivity|
|Clinical Setting(s): Refractory (FDA, NCCN), Relapse (FDA, NCCN)|
|Note: Enasidenib is an IDH2 inhibitor approved by the FDA for treatment of adult patients with relapsed or refractory AML with an IDH2 mutation.|
IDH2 R140G serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains IDH2 R140G as an inclusion criterion, 1 is phase 1/phase 2 (1 open).
Trials with IDH2 R140G in the inclusion eligibility criteria most commonly target glioblastoma, glioblastoma, IDH-wildtype, acute myeloid leukemia, anaplastic astrocytoma, and gliosarcoma .
Radiation therapy, idh2 inhibitor ag-221, vbi-1901, abemaciclib, and bevacizumab are the most frequent therapies in trials with IDH2 R140G as an inclusion criteria .
Significance of IDH2 R140G in Diseases
Acute Myeloid Leukemia +
IDH2 is altered in 10.54% of acute myeloid leukemia patients .
IDH2 R140G is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains IDH2 R140G and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
Enasidenib has evidence of efficacy in patients with IDH2 R140G in acute myeloid leukemia .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.